Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Chemotherapy. Radiation. UAB Department of Neurology , Birmingham, AL, United States

Survival: 16.3 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: United States
City/State/Province: Birmingham, AL
Hospital: UAB Department of Neurology
Journal: Link
Date: 5/2015

This phase 2 study involved unmethylated MGMT gene promoter glioblastoma patients who were divided into two separate treatment groups. Group A had 88 patients with a median age of 55.6 years and 56.8% male. Group B had 89 patients with a median age of 57.7 years and 61.8% were male.

Patients in group A received radiation therapy and chemotherapy with temozolomide and cilengitide.

Patients in group B received radiation therapy and chemotherapy with temozolomide.

There were two treatment-related deaths in group A due to thrombocytopenia and pulmonary embolism. Grade 3 or higher lymphopenia, muscular weakness, and rash were also reported.

One treatment-related death due to pancytopenia (decreased numbers of all types of blood cells) was reported in group B. Grade 3 or higher weakness and deep vein thrombosis were also reported.

The median overall survival times for groups A and B were 16.3 and 13.4 months, respectively.

This study was supported by Merck.

Correspondence: Dr. Louis Burt Nabors; email:

E-mail to a Friend Email Physician More Information